Back

An in vivo model for cardiotoxicity of myeloid cell leukemia 1 inhibition (mcl1)

20 June 2025 (13:10 - 14:10)
Organised by: Logo
Congress Presentation Part of: Basic and translational cardio-oncology beyond anthracyclines Research and New Technology CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Ms Zsanett Papdi

University Hospital Heidelberg, Heidelberg (Germany)

9 More presentations in this session

Presentation thumbnail
Gut microbiome correlations with cardiotoxicity biomarkers (LV-GLS, LVEF, Troponin I, NTproBNP) in breast cancer patients prior to chemotherapy
Doctor A. Antoniades (Limassol, CY)
Abstract Slides
Presentation thumbnail
Myocardial expression of immune checkpoint molecules in patients with advanced heart failure
Doctor T. Gergely (Budapest, HU)
Abstract Slides
Presentation thumbnail
The functional role of TOP2beta PARylation in myeloid cells senescence-associated secretory phenotype (SASP) and atherosclerosis induction following ionizing radiation
Professor J. Abe (Houston, US)
Abstract Slides
Presentation thumbnail
Direct effects of the tyrosine kinase inhibitors (TKIs) nilotinib and imatinib on the myocardium: clues towards cardiotoxic profiles
Ms Y. Appels (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
HRASV12G overexpression as a driver of senescence in human cardiac fibroblasts
Doctor A. Costa (Genoa, IT)
Abstract Slides

Access the full session

Session thumbnail
Basic and translational cardio-oncology beyond anthracyclines

The Event

Event poster

ESC Cardio-Oncology 2025

20 June 2025 13:10 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources